

**Unidad de Ensayos Clínicos****Agencia Española del Medicamento y Productos Sanitarios (AEMPS)**

Parque Empresarial Las Mercedes, Edificio 8

C. Campezo, 1

28922 Madrid

**European Medicines Agency (EMA)**

Domenico Scarlatti laan 6

1083 HS Amsterdam

The Netherlands

Subject	To state reasons for the trial premature interruption
Study Title	Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.
Protocol code	EGRADICATE
EudraCT Number	2015-005453-13
Product	Zepatier® (Grazoprevir + Elbasvir), Ribavirin
Sponsor	Fundació Clínic per a la Recerca Biomèdica
Trial end	1-Jun-2017

07, March, 2025

Dear sir/madam,

The trial was a single centre study conducted in Spain.

This trial was approved by the Spanish authorities but ended prematurely.

This study was not a Low Intervention Trial.

The active site was: Hospital Clínic de Barcelona, C/ Villarroel 170, 08036 (Barcelona)

**Harmonised Protocol (version 1.1, 01-Aug-2016):**

Member State	Date of approval		
	National Competent Authority	Ethics Committee	Name of Ethics Committee
SPAIN	3-Aug-2016	29-Jul-16	CEIC Hospital Clínic de Barcelona

## Declaration

The sponsor, Fundació de Recerca Clínic Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), hereby declares that the clinical trial with EudraCT Number 2015-005453-13 ended prematurely on 1-Jun-2017.

The trial never started due to issues of delay in the manufacturing and distribution of the investigational drug by the manufacturer and distributor.

Please do not hesitate in contacting us should you need further information.

Yours faithfully,

Sara Campos  
Application Submitter CTU CLINIC